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Surfactant proteinsMaturation of pulmonary fetal type II cells to initiate adequate surfactant production is crucial for postnatal
respiratory function. Little is known about speciﬁc mechanisms of signal transduction controlling type II cell
maturation. The ErbB4 receptor and its ligand neuregulin (NRG) are critical for lung development. ErbB4 is
cleaved at the cell membrane by the γ-secretase enzyme complex whose active component is either
presenilin-1 (PSEN-1) or presenilin-2. ErbB4 cleavage releases the 80 kDa intracellular domain (4ICD), which
associates with chaperone proteins such as YAP (Yes-associated protein) and translocates to the nucleus to
regulate gene expression. We hypothesized that PSEN-1 and YAP have a development-speciﬁc expression in
fetal type II cells and are important for ErbB4 signaling in surfactant production. In primary fetal mouse E16,
E17, and E18 type II cells, PSEN-1 and YAP expression increased at E17 and E18 over E16. Subcellular
fractionation showed a strong cytosolic and a weaker membrane location of both PSEN-1 and YAP. This was
enhanced by NRG stimulation. Co-immunoprecipitations showed ErbB4 associated separately with PSEN-1
and with YAP. Their association, phosphorylation, and co-localization were induced by NRG. Confocal
immunoﬂuorescence and nuclear fractionation conﬁrmed these associations in a time-dependent manner
after NRG stimulation. Primary ErbB4-deleted E17 type II cells were transfected with a mutant ErbB4 lacking
the γ-secretase binding site. When compared to transfection with wild-type ErbB4, the stimulatory effect of
NRG on surfactant protein mRNA expression was lost. We conclude that PSEN-1 and YAP have crucial roles in
ErbB4 signal transduction during type II cell maturation., membrane; Nuc, nuclear
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1.1. Fetal lung surfactant production
Respiratory distress syndrome (RDS) of the newborn occurs as a
result of insufﬁcient surfactant production due to prematurity.
Despite the beneﬁcial effects of prenatal glucocorticoids and postnatal
surfactant replacement therapies, RDS remains one of the signiﬁcant
causes of morbidity and mortality in premature infants [1,2].Surfactant synthesis and release take place in the alveolar
epithelial type II cells. Type II cell maturation in the fetal lung is
under multifactorial control, in which paracrine mesenchymal-type II
cell communication mechanisms play a central role. We have shown
that the growth factor Neuregulin (NRG-1), which is secreted by
ﬁbroblasts, plays a prominent role in this paracrine mesenchymal–
epithelial cell communication by stimulating maturation of surfactant
synthesis in fetal lung type II cells [3]. NRG is a ligand of the ErbB3 and
ErbB4 receptors. We have shown that ErbB4 signaling in fetal type II
cells in response to NRG or fetal lung ﬁbroblast conditioned medium
(FCM) is a potent stimulator of type II cell maturation and surfactant
synthesis [4,5].
1.2. ErbB receptor biology
The ErbB4 receptor is a member of the ErbB family of tyrosine
kinase receptors, which also includes ErbB1 (EGF receptor), ErbB2,
and ErbB3. All four receptors are transmembrane tyrosine kinase
proteins and act as important regulators of cell proliferation and
differentiation during fetal organ development, most notably in the
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importance of ErbB4 in lung development, especially for type II cell
maturation, is now becoming evident. ErbB4 is the most prominent
dimerization partner in fetal lung type II cells. ErbB4 down regulation
in type II cell cultures using siRNA blocks NRG and FCM stimulation of
surfactant production. ErbB4 deletion in vivo leads to delayed fetal
lung development [10] and alveolar simpliﬁcation, a hyper reactive
airway system, and signs of chronic inﬂammation in the adult
lung [11].
ErbB4 signal transduction is a complex process. Binding of NRG in
the extracellular ligand binding site causes ErbB4 to form homo- or
heterodimers with other ErbB receptors linked by disulﬁde bonds in
the extracellular domain. These receptor dimers then undergo
autophosphorylation on tyrosine residues within the intracellular
domain. The tyrosine phosphorylation may then activate signal
cascades through speciﬁc intracellular signaling pathways such as
the PI3 kinase/Akt pathway to ultimately inﬂuence gene expression. A
more recently discovered novel signaling mechanism involves
enzymatic cleavage of activated ErbB4 at the intracellular membrane,
releasing an 80 kDa intracellular fragment that translocates to the
nucleus where it interacts with DNA to directly regulate gene
expression. We have reported the presence of ErbB4 in the nucleus
of fetal lung type II cells in culture [12]. The signaling mechanisms of
ErbB4 in fetal lung type II cells have not been studied.
The novel nuclear trafﬁcking mechanism of ErbB4 signaling is
initiated by a two-step cleavage process that is induced by the binding
of NRG [13–15]. The initial proteolysis is performed by the
transmembrane metalloproteinase TACE (Tumor Necrosis Factor-
alpha Converting Enzyme, also known as ADAM 17) [16]. This
ectocytic cleavage produces an ectodomain fragment of 120 kDa and
a membrane-associated 80 kDa (m80) fragment, which includes the
transmembrane and cytoplasmic domains of ErbB4 [17]. The second
cleavage step is endocytic cleavage within the transmembrane
domain by γ-secretase, releasing the intracellular domain (4ICD)
[13,18]. γ-Secretase is an enzyme complex that consists of 4
components. The enzymatically active component is one of the
polytopic membrane proteins presenilin-1 (PSEN-1) or presenilin-2
(PSEN-2). The other three identiﬁed components are Nicastrin, the
Anterior Pharynx Defective-1 (APH-1), and the Presenilin Enhancer
Protein (PEN-2). These behave as essential cofactors for PSEN-1 or
PSEN-2 [19–25]. The action of γ-secretase alters the ErbB4 m80
fragment to release the soluble s80 fragment 4ICD, which is found in
the cytosol and in the nucleus [15,26]. The s80 fragment of ErbB4
associates at least with one chaperon protein, for example, Yes-
associated protein (YAP), for transport to the nucleus. YAP was one of
the ﬁrst proteins shown to act as a chaperon protein for ErbB4 [27]. A
serine residue in YAP is phosphorylated by the protein kinase Akt, and
it subsequently associates with 14-3-3 proteins [28,29]. This binding
facilitates the translocation of the ErbB4-YAP-complex from the
cytosol to the nucleus [30].
Nuclear localization of ErbB4 is the preferred mechanism of ErbB4
signaling in at least one signiﬁcant regulatory process during
development [31]. We propose that nuclear localization of ErbB4 is
important for signaling in type II cell surfactant production. In order to
deﬁne the mechanisms of nuclear localization of ErbB4 in fetal lung
type II cells during development and to determine the role of this
signaling pathway in the development of surfactant synthesis, we
studied the developmental regulation of PSEN-1 and YAP in fetal
mouse type II cells, their activation and association with ErbB4 in
response to NRG, and the importance of γ-secretase-mediated ErbB4
nuclear localization for surfactant protein mRNA production. We
hypothesized that PSEN-1 and YAP are developmentally regulated in
fetal type II cells and that the pathway by which ErbB4 activation
in fetal type II cells initiates surfactant protein mRNA production
involves activation of PSEN-1 and YAP with nuclear localization
of ErbB4.2. Methods and materials
2.1. Materials
All animal use was approved by the institutional IACUC. Timed-
pregnant Swiss Webster Mice were obtained from Taconic Farms
(Germantown, NY). Dulbecco's modiﬁed Eagle's medium (DMEM),
epidermal growth factor (EGF), and monoclonal mouse anti-ß actin
(Actb) were purchased from Sigma (St. Louis, MO). Neuregulin 1β
(NRG) was kindly provided by Dr. Kermit Carraway III (UC Davis, CA)
and puriﬁed by Dr. Ann Kane, Phoenix Laboratory (Tufts Medical
Center, Boston, MA). Paraformaldehyde was obtained from Fisher
Scientiﬁc (Fair Lawn, NJ); OCT (optimal cutting temperature embed-
ding medium) was from Miles Laboratories (Elkhardt, IN); Superfrost
Plus slides were from Fisher Scientiﬁc (Pittsburgh, PA); avidin, biotin,
normal goat serum, and alkaline phosphatase chromogen solution
were from Vector Laboratories (Burlingame, CA). Alexa Fluor 488 and
568were obtained from Invitrogen (Carlsbad, CA). Monoclonal mouse
anti-PSEN-1 was from Afﬁnity Bio Reagents (Golden, CO). Polyclonal
rabbit anti-PSEN-1 and rabbit anti-phospho-PSEN-1 antibodies were
obtained from Abcam (Cambridge, MA). Polyclonal rabbit anti-YAP
and anti-phospho-YAP antibodies were purchased from Cell Signaling
Technology (Danvers, MA). Monoclonal anti-phospho-tyrosine was
obtained from Cell Essentials (Boston, MA). Monoclonal mouse anti-
YAP and polyclonal rabbit anti-ErbB-4 (C-18) antibodies were from
Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal mouse anti-
LAP2 antibody was from BD Transduction Laboratories (San Jose, CA).
HRP-linked polyclonal goat anti-rabbit and goat anti-mouse anti-
bodies were from Perkin Elmer Life Science (Boston, MA). Protein A
sepharose CL-4B was from Amersham Bioscience (Uppsala, Sweden).
Plastic tissue culture dishes, ﬂasks, 6-well and 12-well plates were
purchased from BD Bioscience (San Jose, CA). Fetal calf serum (FCS)
was from Hyclone (Logan, UT). Hank's balanced salt solution (HBSS)
and DNase were from Gibco (Grand Island, NY). BCATM Protein Assay
Reagents were from Thermo Scientiﬁc (Rockford, IL). Precision
Standards Dual Color and pure nitrocellulose membranes were
obtained from Bio-Rad Laboratories (Palo Alto, CA). NanofectinTM
was from PAA-Laboratories (Pasching, Austria). Total RNA Isolation
Reagent was from ABgene (Darmstadt, Germany); the forward
primers (FP), reverse primers (RP) and probes speciﬁc for beta actin
(Actb), surfactant protein A1 (Sftpa1), surfactant protein B (Sftpb),
surfactant protein C (Sftpc), surfactant protein D (Sftpd), and the Sftpb
promoter were from Eurogentec (Cologne, Germany). TaqMan
Universal PCR Master Mix and ABI PRISMTM Big Dye Terminator
Cycle Sequencing Ready Reaction Kit were from Applied Biosystems
(Darmstadt, Germany). Plasmid Midi Kit was from Qiagen (Hilden,
Germany). First-Strand cDNA Synthesis Kit was from Amersham
Biotechnologies (Munich, Germany).
2.2. Whole lung immunostaining
PSEN-1 and YAP expression were examined in whole lung sections
from fetal mice of gestation E16, E17, and E18 in a modiﬁcation of
methods we have previously described [32]. Brieﬂy, lungs were ﬁxed in
PBS (phosphate-buffered saline) containing 4% PFA (paraformaldehyde),
pH 7.2, for 4 h and incubated in PBS with 30% sucrose overnight at 4 °C.
The lungs were embedded in OCT, cut into 8-μm sections in a cryostat
at −21 °C and washed with 100% acetone for 2 min at −21 °C. Several
slides were thawed to room temperature and washed for 1 h in sterile
ﬁltered PBS containing 0.1% Tween (PBST). All subsequent washes were
done in PBST. Non-speciﬁc bindingwas prevented by sequential blocking
by avidin (15 min), biotin (15 min), and 1.5% normal goat serum
(30 min). Control sections were then incubated with PBS, one group of
the experimental samples was incubated with PSEN-1 antibody (1:200),
the other group with YAP antibody (1:200) overnight at 4 °C. Next,
sections were sequentially incubated with goat anti-rabbit biotinylated
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alkaline phosphatase for 30 min. After a last washing with distilled H2O
for 10 min, the sections were ﬁnally counterstained with Vector fast red
and analyzed by light microscopy.
2.3. Mouse type II cell isolation and NRG stimulation
Fetal mouse lung type II cells were isolated and cultured as
described before [3]. Brieﬂy, mice were sacriﬁced with CO2 inhalation
at E16, E17, and E18 of gestation (term=E19). The fetuses were
removed. The lungs were transferred into HBSS (Hank's buffered
saline solution) on ice, minced into 1 mm³ pieces, and digested in
DMEM (Dulbecco's modiﬁed Eagle's medium) containing 0.1% type II
collagenase for 2 h at 37 °C and 30 min on ice. The cells were
centrifuged at 650×g for 5 min at 4 °C, resuspended in DMEM, and
incubated on ice for 30 min, followed by a second 650×g centrifuga-
tion. The cell pellet was dissociated with HBSS containing 0.25%
trypsin and DNase (20 μg/ml) for 12 min at 37 °C. This reaction was
inhibited by adding DMEM with 10% FCS. The cells were ﬁltered
through sterile nitex ﬁlters and centrifuged at 650×g for 10 min at
4 °C. The pellet was resuspended in DMEMwith 10% FCS, and the cells
were placed into 100 mm dishes (4–5 lungs/dish) for 1 h at 37 °C to
provide a ﬁrst ﬁbroblast adherence. The supernatant was then
centrifuged for 5 min at 4 °C. The pellet was resuspended in DMEM
with 10% FCS and placed into T75 ﬂasks (7–8 lungs/ﬂask) for 75 min at
37 °C to allow a second differential adherence step. The medium
containing the non-adherent cells was once again removed and
centrifuged as described before, resuspended in DMEMwith 20% FCS,
plated into 12-well plates, and incubated overnight at 37 °C. The non-
adhesive cells were gently washed away with PBS. Using staining for
lamellar bodies, we have shown 89% purity of fetal mouse type II cells
with this culture procedure.
Experiments using NRG administration were conducted when
the type II cells appeared 80% conﬂuent. Cells received 33 nM NRG for
a 5-min period, except for experiments using confocal microscopy, in
which the duration of NRG was as stated in the Results section. The
NRG dose is consistent with those commonly used to evaluate acute
ErbB4 receptor activation and initiation of signal transduction, and
they are referred to hereafter as stimulation experiments.
2.4. Subcellular fractionation
Subcellular fractionation experiments were done as we have
described [33]. Brieﬂy, 40 wells each of 12-well plates, untreated and
stimulated E17 type II cells, were washed 3 times with ice-cold PBS
and scraped in 100 μl homogenization buffer (20 mM Tris–HCl,
250nM sucrose, 1 mM EGTA, 1 mM Dithiothreitol, 1 mM PMSF)
containing protease inhibitors (1 μg/ml Pepstatin, 10 μg/ml Leupeptin,
10 μg/ml Phosphoamidon) and phosphatase inhibitor cocktail
(250 mM NaF, 200 mM beta-glycerophosphate, 50 mM tetrasodium
pyrophosphate, 50 mM Hepes, 25 mM EDTA, distilled H2O). After 10
passes of sonication, the suspension was centrifuged for 10 min at
800×g at 4 °C. The supernatant was further processed to isolate
membrane and cytosolic fractions. After centrifugation at 100,000×g
for 45 min at 4 °C the top layer was transferred into Centricon tubes,
centrifuged for 30 min at 5000×g at 21 °C and then for 3 min at 750×g
at 4 °C. The remaining ﬂuid was collected as the cytosolic fraction. The
pellets from the original 100,000×g centrifugation centrifuge tubes
were resuspended in 250 μl of homogenization buffer with all
protease inhibitors and 1% Triton X-100 and vortexed vigorously for
1.5 h, followed by centrifugation at 100,000×g at 4 °C for 30 min. The
supernatant was collected as the membrane fraction. The samples
were analyzed by Western blotting. To ensure that we did not lose
protein between the centrifugation steps, we measured protein
amounts of the supernatants after the 3 main centrifugation steps(10-min centrifugation, 45-min centrifugation, and puriﬁed samples).
In total the protein loss was less than 3%.2.5. Co-immunoprecipitation and Western blotting
At 80% conﬂuence, the cells were serum starved for 3 h, stimulated
for 5 min with NRG (33nM) or with DMEM (untreated). The cells were
washed with ice-cold PBS and harvested in co-immunoprecipitation
buffer (20 mM Tris (pH 7.4), 150 mM NaCl, 1 mM MgCl2, 1% Triton
X-100, 10% Glycerol, 1 mM Na3Vo4, 1 mM NaF, 1 mM ZnCl2, 10 mM
beta-glycerol-phosphate, 5 mM tetrasodium pyrophosphate, 1 mM
PMSF, 4 μg/ml each of aprotinin, leupeptin, pepstatin). Aliquots
(200 μg protein) of whole cell lysates were incubated with the speciﬁc
antibody (PSEN-1 or YAP) for 1.5 h at 4 °C. After adding Protein-A
Sepharose, the sample was incubated with gentle rocking over night
at 4 °C. The following day, the beads were washed 3 times with
co-immunoprecipitation washing buffer (20 mM Hepes (ph7.4),
150nM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM Na3VO4, 1 mM NaF,
10 mM beta-glycerol phosphate, 5 mM tetrasodium pyrophosphate,
1 mMPMSFand4 μg/ml eachof aprotinin, leupeptin, andpepstatin) and
between washes microcentrifuged at 100×g at 4 °C for 10 min. The
supernatant was removed into Laemmli buffer for 5 min at 100 °C.
The proteins were separated using an 8% SDS-gel and transferred
to nitrocellulose membranes. The blots were stained with Ponceau's
to conﬁrm efﬁcient transfer. After blocking in 1% BSA in TBST for 1 h,
the membranes were incubated with anti-phospho-tyrosine, anti-
phospho-YAP, anti-phospho-PSEN-1, anti-ErbB4, anti-YAP, and anti-
PSEN-1 antibodies overnight at 4 °C. The proteins were visualized by
enhanced chemiluminescence.2.6. Confocal microscopy
Type II cells from E17mice were cultured on glass cover slips. After
3 h of serum starvation, the cells were incubated with DMEM
(untreated) or stimulated for 5 min, 30 min and 24 h with NRG
(33nM), then prepared for confocal imaging. Cells were washed with
PBS; all subsequent washes were done with PBS. Cells were ﬁxed for
20 min with 3% PFA (pH 7.2), permeabilized with PBS containing 0.5%
Triton X-100 for 5 min at 4 °C, and blocked with 10% normal goat
serum for 1 h. After further incubating with primary antibody against
PSEN-1 or YAP plus ErbB4 antibody for 30 min at room temperature,
cells were incubated with secondary antibodies with ﬂuorochrome
labels (Alexa 488 and 568) for 30 min at room temperature in the
dark. Finally, the cells were incubated with DAPI containing mounting
medium over night at room temperature. Cells were analyzed using a
Leica TCS-SP2 confocal laser scanning microscope.2.7. Nuclear fractionation
For nuclear fractionation, untreated and stimulated (5 min,
30 min, 24 h) E17 type II cells were lysed in nuclei buffer (pH 7.9,
10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 1% Triton X-100, 0.5 mM
DTT) as described before [34]. The suspension was kept on ice for
10 min and centrifuged at 10,000×g at 4 °C for 10 min. The super-
natants (cytoplasmic fractions) were stored at−80 °C and the pellets
(containing the nuclear fractions) were suspended in High Salt Buffer
(pH 7.9, 10 mM HEPES, 400 mM NaCl, 0.1 mM EDTA, 5% glycerol,
0.5 mM DTT), kept on ice for 20 min, and centrifuged at 10,000×g at
4 °C for 10 min. The ﬁnal supernatants (nuclear fractions) were stored
at−80 °C until further use. Proteins of the different cell fractionswere
analyzed by Western blotting and probed for the 80 kDa ErbB4
fragment (4ICD), YAP, Lap2 (a nuclear marker), and for ActB as an
internal standard.
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Type II cells were cultured in 6-well plates for 24 h at a cell density
of 1×106 cells/ml. Transfections were performed as described by the
manufacturer. Brieﬂy, 1 μg DNA of pEGFP N3 (control plasmid),
pHER4 GFP (full-length ErbB4 receptor), or pHER4V673IMU (mutant,
defective in the γ-secretase binding site) was diluted with Nanofectin
transfection reagent and incubated for 30 min before it was added
drop-wise into the serum-containing medium. Cells were harvested
after 48 h of transfection for real-time PCR.
2.9. RNA isolation and cDNA synthesis
After transfection cells were lysed in RNA isolation reagent. RNA
was isolated by acid phenol/chloroform extraction [35]. Five micro-
grams of total RNA was used for reverse transcription using a cDNA
synthesis kit (GE Healthcare) in a 15 μl reaction volume containing 1×
DTT, 0.2 μg hexamer primer, and 5× bulk mix for 1 h. The resulting
cDNA was used for real-time ampliﬁcation reactions.
2.10. Quantitative real-time PCR
The cDNA levels for Sftpa1, Sftpb, Sftpc, Sftpd, and Actb gene
transcripts were measured by real-time PCR as previously described
[11]. Actb was used as an internal control to normalize the surfactant
protein cDNA levels. The 20 μl reaction mixture contained 1 μl of the
cDNA template, 10 μl TaqMan universal master mix (Applied
Biosystems), 300 nM each of forward and reverse primer, and
200 nM probe. For ampliﬁcation and detection of speciﬁc products,
the ABI PRISM 7500 sequence detection system was used (Applied
Biosystems). The ampliﬁcation protocol consisted of an initial
denaturation and enzyme activation at 95 °C for 10 min, followed by
45 cycles at 95 °C for 15 s and 60 °C for 1 min. The threshold cycle was
determined for each gene [36]. Samples were run in quadruplicates.
The method of Seiffert et al. was used to estimate the relative
expression level of the surfactant protein genes by calculating the DCt
value, representing the difference in the Ct values of the target and the
reference gene [37]. The differences in the Ct values of the ErbB4
transfected cells compared to cells transfected with the EGFP control
plasmid were calculated as DDCt and represented as DDCt−1 (DDCt
values are inversely proportional to the levels of Sftp mRNA). For each
assay, speciﬁcity was conﬁrmed by sequencing the PCR products on
both strands using capillary electrophoresis with POP-6TM-Polymer
on an ABI 3100 Genetic Analyzer (Applied Biosystems).
2.11. Data analysis
All data are presented as mean±SEM of experimental-speciﬁc
controls unless otherwise stated. Two-tailed t-tests were used to
evaluate the results for statistical signiﬁcance, using the Instat
statistical package (GraphPad Software, San Diego, CA).
3. Results
3.1. Cell-speciﬁc expression of PSEN-1 and YAP
Immunohistochemistry showed changes with gestation in both
PSEN-1 and YAP immunolocalization in E16, E17, and E18 female fetal
mouse lungs (Fig. 1). At E16 (Fig. 1B) PSEN-1 protein was weakly seen
in cytoplasm of cuboidal epithelium and in surrounding mesenchyme.
The columnar epithelium of bronchiolar airways (asterisk) was
negative. PSEN-1 expression at E17 (Fig. 1C) and E18 (Fig. 1D) was
increased in cuboidal epithelium and in the epithelium at the
transition from distal bronchioles to alveolar ducts (asterisk in
Fig. 1C), compared to E16 lung sections. Mesenchymal cells adjacent
to cuboidal epithelium were also strongly positive but clusters ofmesenchymal cells between the airways were less positive. YAP
staining was weak at E16 (Fig. 1E), changing to a strong expression at
E17 (Fig. 1F) and E18 (Fig. 1G) in cuboidal epithelium, particularly at
the tips of alveolar ducts. Low cuboidal epithelium (asterisk in 1F)was
also positive at E17 and E18. YAP staining was minimally present in
mesenchyme (arrowheads in Fig. 1F and G).
3.2. Gestational regulation of PSEN-1 and YAP protein expression
Western blotting of whole cell lysates was used to identify the
gestational regulation and the effect of NRG on PSEN-1 and YAP
(Fig. 2A). Gestational regulation was identiﬁed by expressing the
densitometry values of unstimulated (no NRG) E17 and E18 results as
a percent of baseline E16. The effects of NRG stimulation were
evaluated by comparing the changes of protein expression on
densitometry to the endogenous expression of their respective
gestation-speciﬁc unstimulated controls. PSEN-1 exhibited a strong
gestational increase in E17 type II cells to 181%±17% (mean±SE,
p=0.0006, n=6) and in E18 type II cells to 172%±20% (mean±SE,
p=0.007, n=6) compared with E16 cells (100%±1%, n=6) (left
panel, Fig. 2B). The development of YAP expression in type II cells
showed patterns of gestational regulation and NRG effects quite
similar to that of PSEN-1. Endogenous YAP baseline expression was
increased to 243%±35% in E17 type II cells (mean±SE, p=0.002,
n=4) and to 207%±29% in E18 type II cells (mean±SE, p=0.004,
n=4) compared to E16 cells (100%±1%, n=4) (right panel, Fig. 2B).
Five-minute stimulation with NRG did not signiﬁcantly change the
amount of PSEN-1 on any day (E16 100%±6%; mean±SE, p=0.9,
n=3; E17 99%±10%; mean±SE, p=0.9, n=3; E18 104%±13%;
mean±SE,p=0.7,n=3), or theamount of YAP (E1697%±5%;mean±
SE, p=0.4, n=3; E17 108%±8%; mean±SE, p=0.3, n=3; E18 99%±
7%; mean±SE, p=0.9, n=4).
3.3. Cellular distribution of PSEN-1 and YAP
We performed subcellular fractionations to determine the cellular
distribution of PSEN-1 and YAP at baseline and after NRG stimulation
(Fig. 3A). Wemeasured the amount of protein in the cytosolic fraction
using ActB as an internal standard. Although some Actb is necessarily
found in the membrane fraction, we were not conﬁdent that this
would be a consistent proportion. Therefore, we quantiﬁed the
membrane fraction as the ratio between the membrane protein
and the Actb-standardized cytosolic protein. As would be expected,
PSEN-1 andYAPwere present in themembrane andmore prominently
in the cytosolic fractions. In NRG-stimulated cells, the membrane/
cytosol ratio of PSEN-1 was signiﬁcantly increased to 144%±12%
(mean±SE, p=0.02, n=3) in E17 type II cells and to 140%±16%
(mean±SE, p=0.01 n=3) in E18 cells compared to their gestational
speciﬁc unstimulated ratios. NRG also induced an increase of the YAP
membrane/cytosol ratio in E17 cells (121%±12%;mean±SE, p=0.03,
n=3), and in E18 cells (125%±13%; mean±SE, p=0.02, n=3),
suggesting a relocation of PSEN-1 and YAP to themembranewith NRG
stimulation. This effect was not seen in E16 cells for either the PSEN-1
membrane/cytosol ratio (103%±5%; mean±SE, p=0.7, n=3) or the
YAP membrane/cytosol ratio (103%±2%; mean±SE, p=0.1 n=3)
(Fig. 3B).
3.4. Effects of NRG on cellular localization and co-localization of ErbB4
with PSEN-1 and ErbB4 with YAP
Confocal microscopy was used to conﬁrm the subcellular fraction-
ation results and to learn more about cellular co-localization of ErbB4
with both PSEN-1 and YAP. As we have previously reported [12],
ErbB4 (red) at baseline was found at the cell membrane, within the
cytoplasm and diffusely in the nucleus. PSEN-1 (green) at baseline
was primarily seen in the nucleus and more weakly in the cytoplasm
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more prominent in the perinuclear region and in the nucleus.
Although the nuclear ErbB4 signal in Fig. 4A is less strong than atFig. 1. PSEN-1 and YAP immunohistochemistry in E16, E17, and E18 fetal mouse lungs. In the
seen in the cytoplasm of the cuboidal epithelium (arrows in B) and in surrounding mesench
negative. Expression of PSEN-1 at E17 (C) and E18 (D) increases in cuboidal epithelium (arro
Mesenchymal cells adjacent to cuboidal epithelium are also strongly positive but cluster
speciﬁcally in E18 (D). YAP cellular expression is minimal at E16 (E), but at E17 (F) and E18 (
ducts. Low cuboidal epithelium (asterisk) is also positive at E17 and E18. Minimal YAP staibaseline, we have shown in several papers that nuclear ErbB4 is strong
after 5 min of NRG stimulation (see also Fig. 4B) [12] [4]. However, the
important ﬁnding in this ﬁgure, which is also consistent with all ourabsence of primary antibody (A), no blue staining is seen. At E16 (B), PSEN-1 protein is
yme (arrowheads). However, columnar epithelia of bronchiolar airways (asterisk) are
ws) and epithelium of distal bronchioles (asterisk in C) at the entrance to alveolar ducts.
s of mesenchymal cells between airways (arrowheads in C and D) are less positive,
G), expression is present in cuboidal epithelium (arrows) particularly at tips of alveolar
ning is present in mesenchyme (arrowheads in F and G). Scale bars are 50 μm.
Fig. 2. Gestational age-speciﬁc expression of PSEN-1 and YAP. (A)Western blot of whole cell lysates of E16, E17, and E18 type II cells, unstimulated and stimulated with NRG (33nM),
probed for YAP (65 kDa), PSEN-1(46 kDa), and beta actin (ActB) (42 kDa) (B). Densitometry of PSEN-1 and YAP expression in whole type II cell lysates. PSEN-1 expression (left
group) is signiﬁcantly increased at E17 (dark grey bar) (**pb0.0006, n=6) and E18 (light grey bar) (**pb0.007, n=6) compared to E16 (black bar) (n=6). YAP expression (right
group) also is signiﬁcantly increased at E17 (**pb0.002, n=4) and E18 (**pb0.004, n=4) compared to E16 (n=4) cells.
485K. Hoeing et al. / Biochimica et Biophysica Acta 1813 (2011) 480–491previous work, is the perinuclear concentration of ErbB4. After 30 min
of stimulation, PSEN-1 was concentrated in the cytoplasm and in the
nucleus; ErbB4 was found in the same regions and in the cellFig. 3.Gestational age-speciﬁc subcellular localization of PSEN-1 and YAP. (A) Representative
cells (NRG−) and NRG-stimulated (NRG+) cells were probed for anti-YAP (65 kDa), ant
expressed in the unstimulated and stimulated cytosolic fraction (cyt). With NRG stimulatio
compared to unstimulated membrane Fractions. (B) Densitometry analysis shows the quan
NRG stimulation caused an increase in the membrane–cytosol ratio of PSEN-1 in E17 (*pb0
controls. The membrane–cytosol ratio of YAP is also signiﬁcantly increased in E17 (*pb0.03membrane. The overlay showed an increasing co-localization in the
perinuclear area immediately after the 5-min stimulation. After
30 min co-localization was strong in the nucleus. After 24 h of NRGWestern blot of the subcellular fractionation of E16, E17, and E18 type II cells. Untreated
i-PSEN-1 (46 kDa), and anti-Actb antibodies (42 kDa). PSEN-1 and YAP are strongly
n, there is an increase of expression of both proteins in the membrane fraction (mem)
tiﬁcation of NRG-induced PSEN-1 and YAP expression in the membrane–cytosol ratios.
.02, n=3) and E18 (*pb0.01 n=3) type II cells compared to their gestational speciﬁc
, n=3) and E18 (*pb0.02, n=3) type II cells.
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areas, whereas ErbB4 localization was additionally present in the cell
membrane. However, the overlay exhibited weak co-localization in
the nucleus and perinuclear areas compared to earlier time points
(Fig. 4A).
The localization of YAP and its pattern of co-localization with
ErbB4 differed from PSEN-1 (Fig. 4B). At baseline, YAP (green) showed
a nuclear and a scattered cytoplasmic signal. Those regions showed
light co-localization with ErbB4 in the overlay. We observed a
prominent nuclear and punctuate cytoplasmic YAP localization after
5 min of stimulation. At 30 min a diffuse weak YAP signal was present
in the cytoplasm and membrane, while the nuclear signal remained
strong. After 24 h YAP had resumed its baseline pattern. The overlay
exhibited a prominent perinuclear and nuclear co-localization at
5 min of stimulation, which diminished after 30 min and was faint
after 24 h.
3.5. Time course of YAP nuclear re-localization
The observation that YAP precipitated the 4ICD more than the
full-length ErbB4 after NRG stimulation prompted us to investigate
the time course of nuclear localization of the ErbB4 fragment and YAP.
Nuclear fractionation experiments were performed with fetal type II
cells untreated and stimulated for 5 min, 30 min, and 24 h. Western
blots were probed for the ErbB4 fragment, YAP, Lap2 (a nuclear
lamina protein [38]), and beta actin (Fig. 4C). The 4ICD fragment was
mainly present in the nucleus. Comparing untreated and stimulated
nuclear fractions, we noticed the greatest difference in the 4ICD
fragment after 5 min of stimulation, indicating a 4ICD movement
towards the nucleus after short stimulation. YAP was mainly present
in the cytoplasm; however, a smaller amount was permanently
present in the nucleus. Nuclear YAP was also highest at 5 min
stimulation and diminished after 30 min and 24 h. Lap 2 appeared
only in the nucleus, conﬁrming a clean fractionation.
3.6. Co-precipitation of ErbB4 with PSEN-1 and YAP
Confocal co-localization experiments do not conﬁrm protein–
protein association or interaction. Therefore, co-immunoprecipitation
experiments were used to assess interactions between PSEN-1 and
ErbB4 and YAP and ErbB4 in E17 type II cells. For PSEN-1 and ErbB4,
cell lysates were immunoprecipitated with anti-PSEN-1 antibody
under co-immunoprecipitation conditions, then probed to detect both
PSEN-1 and ErbB4. Both the full-length ErbB4 and the 4ICD fragment
co-immunoprecipitated with PSEN-1 (Fig. 5A, representative of 4
experiments), indicating that PSEN-1 associates with ErbB4. Stimu-
lation with NRG enhanced this association, which appeared stronger
for the full-length ErbB4 than for the 4ICD. To assess the co-activation
(i.e., phosphorylation) of ErbB4 and PSEN-1, we probed the blots with
anti-phospho-tyrosine and anti-phospho-PSEN-1 antibodies. As
expected, NRG induced phosphorylation of both ErbB4 and PSEN-1.
We further probed these immunoprecipitants with anti-YAP antibody
but didnotﬁnd any evidence of YAPpull down (Supplemental Figure 1A).
The speciﬁcity of the co-immunoprecipitation reaction was veriﬁedFig. 4. Co-localization of PSEN-1 and YAP with ErbB4 after NRG stimulation. (A) NRG stimula
zero), ErbB4 (red) is present in the cell membrane and diffusely in the nucleus. ErbB4 localiz
cell membrane (30 min). At 24 h ErbB4 localization resembles the baseline pattern. PSEN-1
stimulation, PSEN-1 is increased in the perinuclear cytoplasm (5 min), which weakens at 3
strong co-localization of PSEN-1 and ErbB4 in the perinuclear area (5 min) and within the n
induces co-localization of ErbB4 with YAP. At baseline YAP (green) is present in the nucleu
more prominent in the nucleus and punctuate in the perinuclear cytoplasm (5 min). At 30 mi
overlay shows minimal co-localization of YAP with ErbB4 at time zero. This is followed by
5 min of stimulation. After 30 min, there is co-localization in the nucleus and cell surface,
enhanced nuclear localization of 4ICD and YAP. Nuclear fractionation experiments with feta
were probed for the ErbB4 fragment, YAP, Lap2 (a nuclear lamina protein), and Actb. The 4
amount after 5-min stimulation. YAP, mainly present in the cytoplasm, showed highest nuc
only in the nucleus, conﬁrming a clean fractionation.by simultaneous immunoprecipitations using anti-mouse-IgG probed
for anti-phospho-tyrosine, anti-ErbB4, anti-phospho-PSEN-1, and anti-
PSEN-1 antibodies. The IgG antibody did not co-immunoprecipitate any
of these proteins (Fig. 5A).
Co-immunoprecipitation with anti-YAP antibody was also used to
examine YAP–ErbB4 interactions. We found that YAP also co-
precipitated full-length ErbB4 and its 4ICD fragment, especially in
NRG-stimulated cells. Similar to the PSEN-1 co-immunoprecipitation
results, NRG induced both ErbB4 phosphorylation and phosphoryla-
tion of YAP in E17 type II cells (Fig. 5B, representative of 5
experiments). Densitometry was done on the YAP experiments to
document NRG-induced phosphorylation of the 80 kDa fragment 4ICD
associated with activated YAP. For each protein, the NRG condition
was expressed as the percent of the control condition. As expected,
after NRG stimulation, there was no increase in the amount of
immunoprecipitated YAP (103%±9%; mean±SE, p=0.57, n=5).
There was also no increase of the full-length ErbB4 (103%±26%;
mean±SE, p=0.82, n=5) nor of its phosphorylation (125%±20%;
mean±SE, p=0.10, n=5). The densitometry conﬁrmed NRG
activation of YAP phosphorylation (159%±7%; mean±SE,
p=0.016, n=5), increased amount of the 80 kDa 4ICD with NRG
(140%±29%; mean±SE, p=0.08, n=3), and increased phosphory-
lation of the 80 kDa 4ICD (135%±21%; mean±SE, p=0.006, n=5).
These results indicate, ﬁrst, that YAP associates with both the full-
length ErbB4 and the intracellular ErbB4 4ICD fragment and, second,
that YAP association with the 4ICD fragment is signiﬁcantly enhanced
by NRG stimulation. Whether this represents association with ErbB4
before its endocytic cleavage by presenilin or separate associations
with an intracellularly located full-length ErbB4 and with the 4ICD is
not evident. We also probed the YAP immunoprecipitant with anti-
PSEN-1 antibody. In agreement with the PSEN-1 co-immunoprecip-
itation study, YAP immunoprecipitation did not pull down PSEN-1
(Supplemental Figure 1B). Again, immunoprecipitations using anti-
rabbit-IgG conﬁrmed the speciﬁcity of the YAP co-immunoprecipita-
tion (Fig. 5B).
3.7. Role of y-secretase in ErbB4 stimulation of surfactant protein mRNA
expression
We used transgenic ErbB4 deleted mice (HER4heart (−/−)), in
which the embryos are rescued from the lethal cardiac defects by the
expression of a transgene containing the human ErbB4 (HER4) gene
under control of a cardiac-speciﬁc alpha myosin heavy chain
promoter (α-MHC) [39], to test the role of γ-secretase processing of
ErbB4 in ErbB4-mediated stimulation of fetal surfactant synthesis.
Primary cultures of fetal E17 HER4heart (−/−) type II cells (ErbB4-
naive type II cells) were transfected with a plasmid expressing wild-
type human ErbB4 receptor or a control plasmid (EGFP). Expression of
wild-type ErbB4 (HER4) in the ErbB4 naïve HER4heart (−/−) type II
cells led to a signiﬁcant increase in Sftpa1 (0.6±0.2, mean±SE,
p=0.01, n=4), Sftpb (0.9±0.1, mean±SE, p=0.0001, n=3), Sftpc
(0.3±0.1, mean±SE, p=0.01, n=4), and Sftpd (1.2±0.2, mean±SE,
p=0.0001, n=4) mRNA levels (black bar) compared to cells
transfected with the EGFP control plasmid. Transfection of HER4hearttion induces cellular co-localization of ErbB4 with PSEN-1. At baseline (untreated; time
ation changed to a more perinuclear presence (5 min, 30 min) with reappearance at the
(green) is initially punctate in the cytoplasm and strong in the nucleus. Following NRG
0 min but again becomes evident at 24 h. The overlay shows NRG stimulation induces
ucleus at 30 min. Co-localization has mostly disappeared at 24 h. (B) NRG stimulation
s, the cytoplasm, and the cell membrane. Following NRG stimulation, YAP has become
n YAP is predominantly within the nucleus. It returns to the baseline pattern at 24 h. The
pronounced co-localization in the perinuclear cytoplasm and the cell membrane after
which continues at 24 h. (C) Time course of YAP nuclear localization. NRG stimulation
l type II cells were untreated and stimulated for 5 min, 30 min, and 24 h. Western blots
ICD fragment, mainly present in the nucleus, showed the greatest difference in protein
lear YAP concentration at 5-min stimulation and diminished after that. Lap 2 appeared
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Fig. 5. ErbB4 co-precipitated with PSEN-1 and with YAP. Representative blots of co-immunoprecipitations demonstrating interactions of full-length ErbB4 (190 kDa) and its intracellular
domain (80 kDa)with (A) PSEN-1and (B) YAPwere studied inunstimulated (NRG−) andNRG-stimulated (NRG+,5 min) E17 fetal type II cells, using co-immunoprecipitation conditions.
Protein interactions were analyzed by Western blotting. The left two lanes show the cell lysates, the middle two lanes show the speciﬁc PSEN-1 and YAP immunoprecipitations, and
the right two lanes show unstimulated cell lysates and immunoprecipitations using anti-mouse-IgG (negative control for PSEN-1) and anti-rabbit-IgG (negative control for YAP). Blots of
PSEN-1 co-immunoprecipitation and IgG co-immunoprecipitations were probed with anti-phospho-tyrosine, anti-ErbB4, anti-phospho-PSEN-1, and anti-PSEN-1 antibodies. PSEN-1
co-precipitated full-length ErbB4 and its intracellular fragment. This interaction was increased by NRG stimulation. NRG induced phosphorylation of both ErbB4 and PSEN-1. Blots of
YAP co-immunoprecipitation and IgG co-immunoprecipitationswere reprobedwith anti-phospho-tyrosine, anti-ErbB4, anti-phospho-YAP, and anti-YAP antibodies. YAP co-precipitated
full-length ErbB4 and its intracellular fragment in fetal type II cells. This interactionwas increased by NRG stimulation. NRG induced phosphorylation of both ErbB4 and YAP. Quantitative
data for the YAP co-immunoprecipitations are given in the text. Neither IgG co-immunoprecipitations (A and B) pulled down any of the proteins.
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binding side (HER4 V673IMu) was associated with signiﬁcantly
decreased Sftpa1 (−0.7±0.2, mean±SE, p=0.0003, n=3), Sftpb
(−0.3±0.1, mean±SE, p=0.0014, n=3), and Sftpd (−0.1±0.2,
mean±SE p=0.0024, n=3) mRNA levels compared to the increased
SftpmRNAabundance inwild-typeErbB4 (HER4) transfected cells. Thus
γ-secretase processing of ErbB4 is critical for Sftpa1, Sftpb, and Sftpd
expression in the fetal type II cell. We found no signiﬁcant change in
SftpcmRNA expression after transfection with themutant ErbB4 (HER4
V673IMu) construct (−0.3 ±0.1 mean±SE, p=0.9, n=3) compared
to the wild-type ErbB4 transfected cells (Fig. 6).
4. Discussion
In spite of advances in the prevention of RDS including the use
prenatal glucocorticoids and neonatal treatment with postnatalsurfactant replacement, RDS remains one of the signiﬁcant causes of
morbidity and mortality in premature infants [1,2]. Thus, it is
important to develop new insights into endogenous pathways
regulating the development of surfactant synthesis. We have shown
the important role of ErbB4 receptors and NRG for surfactant
production [3,4,10], but their speciﬁc signaling mechanism(s) in
type II cells to promote maturation and surfactant synthesis is not
understood. We are motivated to determine ErbB4 signaling and
trafﬁcking mechanisms controlling fetal type II cell maturation and
surfactant production to provide a foundation for deﬁning new
therapeutic approaches to prevent and treat RDS.
The aim of this current study was to deﬁne the role of proteins
involved in ErbB4 processing and show that processing is needed for
stimulation of surfactant protein gene expression. We concentrated
on the γ-secretase cleavage step as that is the ﬁnal step in releasing
the 4ICD fragment that trafﬁcs to the nucleus [13,18]. There are
Fig. 6. γ-Secretase activity is required for ErbB4-induced stimulation of surfactant
protein (SP) mRNA expression. ErbB4-naive E17 type II cells isolated from HER4heart
(−/−) animals were transfected with full-length human ErbB4 (HER4; black bars) or
an ErbB4 mutant lacking the γ-secretase binding side (HER4V673IMu; grey bars) and
the effect on Sftp expression was measured by quantitative real time PCR. Introduction
of ErbB4 into these ErbB4 (−/−) type II cells induced a signiﬁcant increase in Sftpa1
(*p=0.01, n=4), Sftpb (**pb0.0001, n=3), Sftpc (*p=0.01, n=4), and Sftpd
(**pb0.0001, n=4) mRNA levels. Preventing γ-secretase-dependent cleavage of
ErbB4 signiﬁcantly inhibited the stimulatory effect of ErbB4 on Sftpa1 (++p=0.0003,
n=3), Sftpb (++p=0.0014, n=3), and Sftpd (++p=0.0024, n=3) mRNA levels.
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γ-secretase complex, PSEN-1 and PSEN-2, which are transcribed from
different genes. Knockoutmice of each exhibit pulmonary phenotypes
[40,41]. While there is some overlap in their function, studies show
that γ-secretase complexes containing PSEN-1 or PSEN-2 have
functionally distinct phenotypes [42,43]. The pulmonary phenotype
of the PSEN-1 knockout consists of poorly developed alveoli and
neonatal death with poorly expanded lungs, while the lungs of PSEN-2
knockout mice develop alveolar wall thickening, alveolar and airway
ﬁbrosis, and hemorrhage. Double knockouts show an exacerbation of
the fetal/neonatal abnormalities of alveolar development. However, no
study has addressed the role of presenilins in signaling for type II cell
maturation and surfactant protein expression.
Our focus on PSEN-1 in this study was motivated by the
more severe developmental phenotype of alveolar maturation in the
PSEN-1 knockout mouse. We also studied the shuttle protein YAP
based on the facts that it was one of the ﬁrst ErbB4 shuttle proteins
described and that YAP knockouts are embryonic lethal, preventing
any prior analysis of its importance for lung development [30,44]. We
performed studies of protein expression and cellular distribution in
E16, E17, and E18 fetal mice type II cells, representing the
development from the late stage of bronchial branching (late
pseudoglandular stage, E16) through the canalicular into the saccular
stage of lung development. During this interval in mouse lung
development surfactant synthesis is initiated (E17) with subsequent
progression to a differentiated alveolar epithelium, which synthesizes
surfactant proteins in abundant quantities [45].
Immunohistochemistry of fetal mouse lungs showed that PSEN-
1 and YAP are primarily located in lung epithelial cells, with
increasing expression as term gestation approached. The localiza-
tion pattern changed from the epithelial cells of larger airways at
E16 to a pronounced saccular expression at E18 of gestation. The
analysis of total protein expression of PSEN-1 and YAP in E16,
E17, and E18 primary cultures of type II cells was consistent with
those results. This developmental pattern reﬂects that of fetal
mouse type II cell maturation, in which E17 is the time when
surfactant production begins and E18 when surfactant synthesis is
well established.
Evaluation of the acute effects of NRG on cellular PSEN-1 and YAP
membrane and cytosolic content after NRG stimulation afforded the
opportunity to evaluate the initiation of this ErbB4 processingpathway. Again, baseline results for PSEN-1 and YAP were consistent
with former ﬁndings. The cytosolic PSEN-1 and YAP content were
highest at E17 and E18. NRG stimulation promoted relocalization of
these two proteins at E17, suggesting involvement of this signaling
pathway in the maturational process. We recognize that the
membrane fraction includes membranes from multiple cell compart-
ments, meaning that this crude subcellular fraction gives limited
information about the exact subcellular compartment localization.
Nevertheless, the results indicate that NRG induces translocation of
both PSEN-1 and YAP from the cytosolic to one or more membrane
compartments.
We used confocal microscopy to obtain additional insight into the
localization of PSEN-1 and YAP and the compartments where they
co-localize with ErbB4. Therein, we recognized a constant nuclear
staining of PSEN-1 in addition to a cytosolic signal. Nuclear localization
of presenilins has been reported in several studies [46–49]. It is clear
from our data that in NRG-stimulated fetal type II cells PSEN-1 associates
with ErbB4 in the cytosol and the nucleus at different time points.
The transport mechanisms of the more than 40 proteins known to
interact with PSEN-1 and/or the γ-secretase complex are poorly
understood [50–52]. The traditional model suggests that substrate
protein–γ-secretase interactions occur at the cell membrane; however,
more recent studies bring this into question, suggesting interactions
in several cellular compartments [53,54]. Overall, our data are consistent
with recent studies addressing the internalization of receptor-tyrosine
kinases, especially ErbB4 [55]. Those studies showed that the intracel-
lular domain of ErbB4 is not only sorted to lysosomes and recycled
to the cell membrane, it is also detected in nucleus, cytoplasm and
mitochondria.
Our co-immunoprecipitation studies identiﬁed speciﬁc protein–
protein interactions between ErbB4 and PSEN-1 and between
ErbB4 and YAP in E17 type II cells. PSEN-1 and YAP antibodies
each precipitated the full-length ErbB4 and the 4ICD. PSEN-1
associated with the full-length ErbB4 and its 80 kDa fragment,
suggesting that γ-secretase alters the membrane associated 4ICD
into a soluble form. It is unclear whether full-length ErbB4 or only
the 4ICD moves into the cell as part of the NRG-induced signaling
process, since we found that YAP was also associated with both
ErbB4 species. However, PSEN-1 and YAP were not simultaneously
associated with ErbB4, suggesting a sequence of processing events.
As expected, NRG stimulation caused enhanced association of
PSEN-1 with ErbB4 and of YAP with the 4ICD fragment and also
increased phosphorylation of these proteins, supporting once more
the model of the interrelationship between NRG stimulation and
ErbB4 processing in the developing type II cell. Nuclear fraction-
ation studies gave us additional insight into the fate of 4ICD and
YAP. We found enhanced nuclear localization of both proteins
early after NRG stimulation, which then returned to the baseline
state, consistent with NRG-induced YAP shuttling of 4ICD into the
nucleus.
We tested the role of γ-secretase processing of ErbB4 in the
maturation of the surfactant system in fetal mouse type II cells using
primary fetal type II cells isolated at E17 from HER4heart mice rescued
from embryonic lethality by expression of a human ErbB4 cDNA under
the control of the cardiac-speciﬁc α-MHC (myosin heavy chain)
promoter [39]. We have previously described the lung phenotype of
adult [11] and fetal [10] HER4heart mice. Lack of ErbB4 in HER4heart
fetal lung cells has been previously conﬁrmed by us [10], as has
documentation of expressed wild-type human ErbB4 transfected into
HER4heart fetal type II cells (Zscheppang et al., submitted). Transfec-
tion of ErbB4-naive type II cells from HER4heart (−/−) E17 animals
with amutant ErbB4 lacking the γ-secretase binding site allowed us to
study the regulatory role of γ-secretase cleavage in ErbB4 signaling in
type II cell surfactant protein expression. When compared to cells
transfected with wild-type ErbB4, the increase of mRNA expression
for Sftpa, Sftpb, and Sftpd was prevented by lack of the γ-secretase
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cleavage of ErbB4 in the developing type II cells.
It is unclear why Sftpa actually decreased in cells transfected with
the ErbB4 mutant compared to untransfected cells. We previously
reported dynamic developmental changes between d17 and d18 in
Sftpa mRNA expression in HER4heart (−/−) mutant lungs [10].
Together, these ﬁndings suggest complex regulation of Sftpa expres-
sion in late fetal development. ErbB4 exists in isoforms that can and
cannot be cleaved at the membrane, and with or without the
chaperone-binding sequence for transport of the 80 kDa fragment.
These different isoforms can have strikingly different effects in cells
[31,56]. Thus, activation of alternate signaling pathways by ErbB4
isoforms not cleaved by PSEN-1 may result in inhibition of Sftpa
expression. The lack of change in Sftpc after ErbB4 rescue may also
indicate that alternate mechanisms support the expression of Sftpc, a
possibility also consistent with our previous studies of the develop-
ment of surfactant protein mRNA production in fetal HER4heart mouse
lungs [10]. The role of ErbB4 processing by PSEN-1 in promoting type
II cell development is currently being addressed in more extensive
studies of type II cell surfactant metabolism using siRNA knockdown
of PSEN-1 in vitro [57].
In conclusion, these studies indicate that ErbB4 signaling in fetal
lung type II cells utilizes the pathway of the PSEN-1-dependent γ-
secretase proteolysis, followed by trafﬁcking with YAP to the nucleus.
γ-Secretase cleavage and nuclear transport are crucial for fetal lung
type II cell surfactant protein mRNA production. Our results
emphasize the importance of PSEN-1 and YAP for ErbB4 signaling in
development and may provide signiﬁcant clues for how to target
ErbB4 biology in developing translational applications.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamcr.2010.12.017.
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